{
  "docId": "019de073-f2d4-7758-94ad-33c5441d40e0",
  "docSlug": "ecbf51e8e3db999397a90a848caaf022",
  "documentTitle": "BioAtla | Investor Presentation Deck | 40 slides",
  "authorId": "bioatla",
  "authorName": "BioAtla",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 10,
  "pageCount": 40,
  "prevPage": 9,
  "nextPage": 11,
  "slideType": "traction",
  "function": "show_traction",
  "density": "dense",
  "nDataPoints": 20,
  "notes": "Includes waterfall plot for partial response and spider plot for longitudinal tumor change.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-f2d4-7758-94ad-33c5441d40e0/10",
  "deckHref": "/decks/019de073-f2d4-7758-94ad-33c5441d40e0",
  "deckJsonHref": "/decks/019de073-f2d4-7758-94ad-33c5441d40e0.json",
  "deckAnchorHref": "/decks/019de073-f2d4-7758-94ad-33c5441d40e0#slide-10",
  "components": [
    {
      "bbox": {
        "h": 0.4,
        "w": 0.4,
        "x": 0.52,
        "y": 0.3
      },
      "kind": "chart",
      "text": "Spider plot of change in target lesion from baseline over time by TmPS status.",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c6c84a59-5db7-4cb7-b04a-738ce21f6ca9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.4,
        "x": 0.05,
        "y": 0.3
      },
      "kind": "chart",
      "text": "Waterfall plot of maximum % change from baseline in sum of target lesions for high TmPS patients.",
      "attrs": null,
      "subkind": "waterfall",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a8f608e6-e448-46db-be91-bc695d8845c3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.6,
        "x": 0.11,
        "y": 0.9
      },
      "kind": "disclaimer",
      "text": "Notes: Multiple cycles of antineoplastic agents received prior to starting treatment with BA3011. *AXL Tumor membrane Percent Score or TmPS = % Score ≥1+; $Tissue biopsy from resection, over 1 year old prior to trial entry. 1 NED = No evidence of disease; 2 Synovial sarcoma patient delayed treatment due to unrelated SAE led to progression",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d98ac566-6192-4dda-b2e0-2db8c1eabe49",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.8,
        "x": 0.05,
        "y": 0.8
      },
      "kind": "list",
      "text": "PR was achieved in 4/7 high TmPS patients receiving the clinically-meaningful 1.8 mg/kg dose; Antitumor activity correlates with higher levels of AXL tumor membrane expression in sarcoma patients",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a6bbfcab-2f56-46cb-b5ea-e517df821349",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.7,
        "x": 0.03,
        "y": 0.08
      },
      "kind": "title",
      "text": "Encouraging Phase 1 results with Mecbotamab Vedotin (BA3011) in refractory sarcoma",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "22535516-c279-4125-9b3e-84d6f00a19ad",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Waterfall chart",
      "slug": "waterfall-chart",
      "agent": null,
      "layer": "slide",
      "matchId": "cc797f63-c32c-4402-b60f-fc40d20b5f7d",
      "evidence": "This slide shows a waterfall plot of maximum % change from baseline in sum of target lesions for high TmPS patients.",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 20,
      "from": 10,
      "beatId": "694c2195-11af-4429-8d9c-84c281cb47f3",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Traction",
      "beatSlug": null,
      "evidence": "The deck presents encouraging Phase 1 and 2 results for BioAtla's CABs",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    },
    {
      "to": 15,
      "from": 9,
      "beatId": "f4e18958-ae31-462b-8d8c-75c41bf4a7a8",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Market Size",
      "beatSlug": "sequoia-pitch-market-size",
      "evidence": "The deck presents the potential market opportunity for BioAtla's CABs",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [
    {
      "to": 20,
      "from": 10,
      "name": "Quick Win Big Bet",
      "slug": "47-quick-win-big-bet",
      "bestFor": "Transformation planning, 100-day plans, resource allocation",
      "matchId": "adaaf91b-c3c7-41d4-a221-86ba71676732",
      "evidence": "The deck presents encouraging Phase 1 and 2 results for BioAtla's CABs",
      "position": 1,
      "objective": "What are the key results and milestones for BioAtla's CABs?",
      "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
      "confidence": 0.7,
      "description": "Separate initiatives into immediate wins and longer-term strategic bets"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}